Rani Therapeutics Holdings, Inc. (RANI): Price and Financial Metrics
GET POWR RATINGS... FREE!
RANI POWR Grades
- RANI scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.71% of US stocks.
- The strongest trend for RANI is in Growth, which has been heading down over the past 179 days.
- RANI's current lowest rank is in the Momentum metric (where it is better than 13.4% of US stocks).
RANI Stock Summary
- RANI's went public 1.01 years ago, making it older than merely 0.47% of listed US stocks we're tracking.
- With a price/sales ratio of 310.86, RANI THERAPEUTICS HOLDINGS INC has a higher such ratio than 98.79% of stocks in our set.
- RANI's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 97.2% of US stocks.
- Stocks that are quantitatively similar to RANI, based on their financial statements, market capitalization, and price volatility, are LASR, ICVX, SNAP, LAZR, and LGVN.
- To dig deeper into the stock's financial statements, go to RANI's page on browse-edgar?action=getcompany&CIK=0001856725.
RANI Valuation Summary
- In comparison to the median Healthcare stock, RANI's price/sales ratio is 50168.42% higher, now standing at 1910.2.
- RANI's price/earnings ratio has moved down 21.3 over the prior 32 days.
- RANI's price/earnings ratio has moved down 21.3 over the prior 32 days.
Below are key valuation metrics over time for RANI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RANI | 2021-08-31 | 1910.2 | -7.4 | -52.8 | -48.9 |
| RANI | 2021-08-30 | 1829.2 | -7.1 | -50.6 | -46.7 |
| RANI | 2021-08-27 | 2071.6 | -8.1 | -57.3 | -53.5 |
| RANI | 2021-08-26 | 2121.4 | -8.3 | -58.7 | -54.8 |
| RANI | 2021-08-25 | 1975.3 | -7.7 | -54.6 | -50.8 |
| RANI | 2021-08-24 | 1839.6 | -7.2 | -50.9 | -47.0 |
RANI Price Target
For more insight on analysts targets of RANI, see our RANI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $24.60 | Average Broker Recommendation | 1.1 (Strong Buy) |
RANI Stock Price Chart Interactive Chart >
RANI Price/Volume Stats
| Current price | $9.58 | 52-week high | $36.27 |
| Prev. close | $9.26 | 52-week low | $8.00 |
| Day low | $9.41 | Volume | 22,000 |
| Day high | $10.41 | Avg. volume | 49,596 |
| 50-day MA | $10.24 | Dividend yield | N/A |
| 200-day MA | $13.17 | Market Cap | 470.95M |
Rani Therapeutics Holdings, Inc. (RANI) Company Bio
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
Latest RANI News From Around the Web
Below are the latest news stories about RANI THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate RANI as an investment opportunity.
Analysts’ Top Healthcare Picks: InflaRx (IFRX), Entera Bio (ENTX)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InflaRx (IFRX – Research Report), Entera Bio (ENTX – Research Report) and Rani Therapeutics Holdings (RANI – Research Report) with bullish sentiments. InflaRx (IFRX) H.C. Wainwright analyst Edward White maintained a Buy rating on InflaRx today and set a price target of $8.00. The company's shares closed last Thursday at $2.56. According to TipRanks. |
8 Best Stocks to Buy According to Billionaire Marc LasryIn this article, we will take a look at the 8 Best Stocks to Buy According to Billionaire Marc Lasry. To skip our analysis of Marc Lasry’s profile, investment strategy, and 13F holdings, you can go directly to see the 3 Best Stocks to Buy According to Billionaire Marc Lasry. Avenue Capital Management is a […] |
Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSAN JOSE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place September 12 - 14, 2022 virtually and in-person. Talat Imran, Chief Executive Officer of Rani, is scheduled to present on Monday, September 12 at 8:30 AM EST / |
Wedbush Sticks to Its Buy Rating for Rani Therapeutics Holdings (RANI)E ratio of -8.02. |
Rani Therapeutics Announces Termination of Public Offering of Class A Common StockSAN JOSE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has terminated the underwritten public offering of its Class A common stock previously announced on August 10, 2022. The termination results from an assessment by the Company's management that current market conditions are not conducive for a |
RANI Price Returns
| 1-mo | 2.02% |
| 3-mo | -9.88% |
| 6-mo | -32.06% |
| 1-year | -47.19% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -41.41% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...